# Siolta Therapeutics

> Siolta Therapeutics is a clinical-stage biopharmaceutical company spun out of UCSF that develops defined-consortia live biotherapeutic products to prevent and treat diseases rooted in a disrupted microbiome. Its lead program, STMC-103H, is an oral multi-strain therapy aimed at preventing atopic diseases such as atopic dermatitis and food allergy in newborns, built on the company's proprietary Precision Symbiotics Platform.

- **Founded:** 2016
- **Headquarters:** San Carlos, California, United States
- **Founders:** Nikole Kimes (Co-Founder & CEO), Susan Lynch (Co-Founder & Scientific Founder (UCSF)), Samir Kaul (Co-Founder (Khosla Ventures))
- **Team size:** ~15 employees
- **Products:** STMC-103H, Precision Symbiotics Platform, Women's health program, Rare pediatric disease program
- **Notable:** Reported positive Phase 2 ADORED results in November 2025: 64% reduction in atopic dermatitis risk in infants completing one year of STMC-103H treatment., Reported a 77% reduction in food allergy risk versus placebo in the ADORED trial., Enrolled 238 newborns across 30 sites in the US and Australia.

## Products & services

- **STMC-103H** — Lead oral multi-strain live biotherapeutic product in Phase 2 development to prevent atopic diseases (atopic dermatitis, food allergy, asthma, allergic rhinitis) in newborns with a family history of atopy. Holds FDA Fast Track Designation.
- **Precision Symbiotics Platform** — Proprietary discovery-to-manufacturing engine combining a human microbiota biobank, in vitro and in vivo therapeutic screening, and anaerobic manufacturing to engineer defined mixed-strain live biotherapeutics.
- **Women's health program** — Planned investigational new drug application applying the platform to a women's health indication.
- **Rare pediatric disease program** — Planned investigational new drug application targeting a rare pediatric disease.

## Achievements

- Reported positive Phase 2 ADORED results in November 2025: 64% reduction in atopic dermatitis risk in infants completing one year of STMC-103H treatment.
- Reported a 77% reduction in food allergy risk versus placebo in the ADORED trial.
- Enrolled 238 newborns across 30 sites in the US and Australia.
- Received FDA Fast Track Designation for STMC-103H.
- Awarded a ~$2.9M NIH grant for large-scale manufacturing optimization.
- Raised over $42M across multiple rounds including a $12M Series C.
- ADORED results accepted as a late-breaking oral presentation at the 2026 AAAAI annual meeting in Philadelphia.

## Latest updates

- **2026-02** — ADORED Phase 2 results scheduled as a late-breaking oral presentation at the AAAAI annual meeting in Philadelphia (Feb 27-Mar 2, 2026).
- **2025-11** — Reported positive Phase 2 ADORED results - 64% reduction in atopic dermatitis risk and a strong food-allergy signal for STMC-103H.
- **2024-03** — Closed a $12M Series C co-led by SymBiosis and Khosla Ventures to advance clinical development.

## Links

- Website: https://sioltatherapeutics.com
- LinkedIn: http://www.linkedin.com/company/siolta-therapeutics
- Twitter/X: https://twitter.com/SioltaThera
- Facebook: https://facebook.com/sioltatherapeutics/

---

Profile page: https://yespress.io/siolta-therapeutics
Published by YesPress — https://yespress.io
Last updated: 2026-07-10